RxDoctor Payments Data

Jeffrey Cohen, MD

Dermatology · New Haven, CTNPI 1689054397

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,641 of the $18,162 with a category attached, or 86.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 61.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $12,160 and has fallen 67.2% since, to $3,984 in 2025.

$18,162in general payments, 2019–2025

Across 36 payments — averaging $504.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$11K
  • Sanofi$4K
  • Novartis$2K
  • GSK$817
  • Regeneron Healthcare Solutions, Inc.$195
  • Amgen$81
  • plus $201 from 4 others

What the payments were for

  • Consulting fees$15,64186%
  • Travel & lodging$1,1837%
  • Food & beverage$1,2307%
  • Education$1091%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,162 in reported general payments places this provider in the 85th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$178,835
Medicare patients
637
Services billed
3,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa81$1,755,365
Dupixent PenDupilumab278$1,420,599
Humira(Cf) PenAdalimumab48$669,236
TremfyaGuselkumab28$369,020
OtezlaApremilast73$351,615
Bimzelx AutoinjectorBimekizumab-Bkzx21$307,659
Taltz AutoinjectorIxekizumab28$244,859
Dupixent SyringeDupilumab38$216,138
StelaraUstekinumab14$182,243
RinvoqUpadacitinib13$81,989
Adalimumab-Adaz(Cf) PenAdalimumab-Adaz16$39,035
OpzeluraRuxolitinib Phosphate16$31,710
JubliaEfinaconazole16$21,663
VtamaTapinarof13$18,952
ZoryveRoflumilast20$17,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$81$351,61573 claims
AbbVieRinvoq$79$81,98913 claims
Dermavant Sciences, Inc.Vtama$14$18,95213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 dermatology providers in Connecticut.

Other dermatology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →